Chemed (CHE) Stock Price & Analysis
CHE Stock Chart & Stats
- Day’s Range
- MXN 9,475.44 - MXN 9,475.44
- 52-Week Range
- MXN 8,346.31 - MXN 9,475.44
- Previous Close
- MXN 9,475.44
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 130.78B
- Enterprise Value
- MXN 7.00B
- Total Cash (Recent Filing)
- MXN 48.43M
- Total Debt (Recent Filing)
- MXN 392.19M
- Price to Earnings (P/E)
- 25.5
- Beta
- -0.03
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 138.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.42%
Bulls Say, Bears Say
Bulls Say
VITAS Growth And Margins
VITAS is demonstrating durable operating momentum through higher admissions, patient census, and reimbursement-supported revenue growth. Strong EBITDA expansion and cost controls indicate that scale and operating discipline can support earnings even as the business manages labor and regulatory pressures.
Roto-Rooter Market Position
Above-industry same-store growth suggests Roto-Rooter is strengthening its competitive position rather than relying only on acquisitions. Its established brand, repeat customers, and multiple lead channels provide a durable platform for continued customer acquisition and service expansion.
Cash Generation And Reinvestment
Strong operating cash generation gives Chemed internal funding for acquisitions, branch development, and shareholder returns. Management's stated minimal leverage and cash generation provide financial flexibility to reinvest in both operating platforms while absorbing normal business volatility.
Bears Say
Roto-Rooter Margin Pressure
Roto-Rooter's profitability is being pressured by higher customer-acquisition and fuel costs, while paid leads are becoming a larger part of the mix. Persistent input and marketing pressures could limit operating leverage and reduce the earnings benefit of continued revenue growth.
VITAS Regulatory And Labor Risk
VITAS faces structural pressure because labor costs have outpaced reimbursement for more than five years, requiring ongoing cost containment to protect margins. Increased fraud-and-abuse reviews also raise the possibility of higher contractual allowances or write-offs over time.
Higher Leverage
The sharp increase in leverage reduces balance-sheet flexibility compared with prior periods and makes earnings more sensitive to operating volatility. Higher debt can also constrain future capital allocation if cash is increasingly needed for obligations rather than acquisitions or shareholder returns.
Chemed News
CHE FAQ
What was Chemed’s price range in the past 12 months?
What is Chemed’s market cap?
When is Chemed’s upcoming earnings report date?
How were Chemed’s earnings last quarter?
Is Chemed overvalued?
Does Chemed pay dividends?
What is Chemed’s EPS estimate?
How many shares outstanding does Chemed have?
What happened to Chemed’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Chemed?
What is the TipRanks Smart Score and how is it calculated?
Chemed Stock Smart Score
Company Description
Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Kevin J. McNamara
- Employees
- 15,811
- Website
- www.chemed.com
- Address
- 2600 First Financial Center, Cincinnati, OH, 45202-4726, US
Chemed (CHE) Earnings & Revenues
CHE Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. VITAS delivered substantial revenue, earnings, admissions, census, margin, and Medicare cap improvements, while Roto-Rooter produced solid revenue and same-store growth, improved collections, and strategic franchise expansion. The principal challenges were Roto-Rooter's declining EBITDA and margin due to marketing and fuel costs, lower near-term margins from acquired franchises, nursing wage growth above reimbursement growth, shorter VITAS length of stay, and increased regulatory review activity. Management nevertheless expressed confidence in full-year adjusted EPS performance and the long-term prospects of both businesses.
View all MX:CHE earnings summariesCHE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 3 | 3 |
| Technical Analysis | 2 | 2 | 2 |
| Moving Averages | 10 | 1 | 1 |
